Literature DB >> 3255914

Problems of myeloma in a community.

N G Flanagan1, J C Ridway, A Jain, C C Platt, A G Irving.   

Abstract

The presenting features of 120 consecutive cases of myeloma diagnosed in a single unit were examined. Screening tests on routine laboratory samples increased the detection rate but did not significantly reduce the percentage of cases presenting with late stage disease. Morbidity was closely related to the incidence of bone involvement already present at diagnosis. About one fifth of cases had reported suspicious symptoms for some considerable time before further investigation was forthcoming. Almost half had 'benefitted' by having concurrent disease which often led to the discovery of myeloma at an early stage. These findings, together with the wide variety of symptomatology and few physical signs, stressed the critical importance of having a high index of suspicion and thus taking suitable blood samples without unnecessary delay.

Entities:  

Mesh:

Year:  1988        PMID: 3255914      PMCID: PMC2429029          DOI: 10.1136/pgmj.64.756.747

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  6 in total

1.  New treatments in myeloma--is cure possible?

Authors:  J S Malpas
Journal:  Postgrad Med J       Date:  1987-06       Impact factor: 2.401

2.  Multiple myeloma on the Fylde coast.

Authors:  N G Flanagan; D S Harry; T Kozlowski; T Sorahan
Journal:  Br Med J (Clin Res Ed)       Date:  1984-10-20

3.  Effective treatment of advanced multiple myeloma refractory to alkylating agents.

Authors:  B Barlogie; L Smith; R Alexanian
Journal:  N Engl J Med       Date:  1984-05-24       Impact factor: 91.245

4.  Prognostic factors and staging in multiple myeloma: a reappraisal.

Authors:  R Bataille; B G Durie; J Grenier; J Sany
Journal:  J Clin Oncol       Date:  1986-01       Impact factor: 44.544

5.  A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.

Authors:  B G Durie; S E Salmon
Journal:  Cancer       Date:  1975-09       Impact factor: 6.860

6.  Evaluation of serum beta 2-microglobulin as a prognostic indicator in myelomatosis.

Authors:  J A Child; S M Crawford; D R Norfolk; J O'Quigley; J H Scarffe; L P Struthers
Journal:  Br J Cancer       Date:  1983-01       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.